CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Bupivacaine +2 moredrug
Likely dose
Bupivacaine 4 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02024724
NCT02024724Phase 4Completed

Phase 4 Study Comparing of Dexamethasone to Triamcinolone for Ultrasound-guided Trigeminal Nerve Block: A Randomized Controlled Trial.

Northwestern University·interventional·Posted Dec 31, 2013·Updated Jul 11, 2017

In Brief

A Phase 4 clinical trial evaluating Bupivacaine, Triamcinolone, and 1 other intervention for Typical Facial Pain and Atypical Facial Pain. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Trigeminal neuralgia is a craniofacial pain syndrome that is typically characterized by unilateral severe, recurrent, electrical pain in one or more distributions of the trigeminal nerve. Current treatment strategies include oral medications as first line therapy with surgical interventions reserved for those patients who are refractory to medications or unable to tolerate medication side effects. Despite these current treatment options, many patients continue to have symptoms. Ultrasound-guided trigeminal nerve block allows for fine adjustment of the needle tip and direct observation of the medicine. Local anesthetic and steroids have been successfully used for diagnostic and or therapeutic nerve pain with great success. Steroids can be short or long acting in duration with varying side effects. If there exists a difference in duration of action, using the longer acting drug will provide a greater period of symptom relief for the patient and may allow the patient to undergo fewer interventional procedures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 31, 2013
Enrollment StartNov 1, 2013
Primary CompletionMar 1, 2016
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.5 years ago

Interventions

Bupivacainedrug

4 mL of 0.25% bupivacaine

Triamcinolonedrug

40 mg of Triamcinolone

Dexamethasonedrug

4 mg of Dexamethasone